R. Yao

发表

Patient and Physician Expectations of Add‐On Treatment With Golimumab for Rheumatoid Arthritis: Relationships Between Expectations and Clinical and Quality of Life Outcomes

C. Zerbini, P. Durez, B. Combe, 2014, Arthritis care & research.

Partial remission in ankylosing spondylitis and non-radiographic axial spondyloarthritis in treatment with infliximab plus naproxen or naproxen alone: associations between partial remission and baseline disease characteristics.

Yeong-Wook Song, Sung-Hwan Park, L. Myasoutova, 2016, Rheumatology.

Continuous Clinical Response Is Associated With a Change of Disease Course in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab.

P. Rutgeerts, P. Gibson, W. Sandborn, 2018, Inflammatory bowel diseases.

Efficacy and safety of golimumab in Indian patients with rheumatoid arthritis: Subgroup data from GO‐MORE study

V. Shobha, B. Dharmanand, Siddharth K Das, 2016, International journal of rheumatic diseases.

Five-year Safety Data From OPUS, A European Observational Safety Registry For Adults With Ulcerative Colitis Treated With Originator Infliximab [Remicade®] Or Conventional Therapy.

J. Lindsay, W. Reinisch, J. Panés, 2019, Journal of Crohn's & colitis.

Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study

C. Zerbini, P. Durez, B. Combe, 2013, Annals of the rheumatic diseases.

Factors influencing the patient evaluation of injection experience with the SmartJect autoinjector in rheumatoid arthritis.

M. Herold, R. Giacomelli, H. Schulze-Koops, 2015, Clinical and experimental rheumatology.

Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents.

M. Blaiss, H. Nolte, David Skoner, 2011, The Journal of allergy and clinical immunology.

Clinical Outcomes in Continuous Clinical Responders with Moderately to Severely Active Ulcerative Colitis: Subanalyses from the PURSUIT-SC Maintenance Study: 1709

P. Rutgeerts, P. Gibson, W. Sandborn, 2014 .

Futility Boundary Design Based on Probability of Clinical Success Under New Drug Development Paradigm

Bo Yang, Yijie Zhou, Ruji Yao, 2016 .

AB0273 Efficacy and safety of add-on golimumab treatment in patients with rheumatoid arthritis receiving concomitant methotrexate or leflunomide

J. Molina, A. Alonso-Ruiz, N. Vastesaeger, 2013 .

AB0281 Remission rates during golimumab treatment for rheumatoid arthritis are associated with differences in baseline disease states across geographic regions in the go-more study

R. Moots, K. Pavelka, P. Durez, 2013 .

THU0178 Comprehensive Disease Control with Golimumab in Patients with Rheumatoid Arthritis

R. Burgos-Vargas, M. Leirisalo-Repo, B. Combe, 2013 .

THU0198 Patient Evaluations of Autoinjectors for Delivery of Subcutaneous Golimumab for Treatment of Rheumatoid Arthritis

H. Schulze-Koops, S. Rednic, N. Vastesaeger, 2013 .